Clinical Trial Update: Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis [Phase 2]

View source ↗

Summary

Amgen's Phase 2 trial of Efavaleukin Alfa for moderately to severely active ulcerative colitis was terminated. Safety and efficacy results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Efavaleukin Alfa (efavaleukin alfa)

Snippet

Sponsor: Amgen | Conditions: Ulcerative Colitis | Phase 2 | Status: TERMINATED | Results posted: 2026-01-13